Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00015899 · ClinicalTrials.gov registry record · Phase 1
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Pediatric Brain Tumor Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
- 9
- Study locations
NCT00015899 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 53 participants, below the 182-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (71% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT00015899, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by Pediatric Brain Tumor Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
- 9
- Study locations
Study Summary
RATIONALE: SCH 66336 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SCH 66336 in treating children with recurrent or progressive brain tumors.
Conditions Studied
Interventions
- DRUG lonafarnib
Study Locations (9)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Children's Hospital of Pittsburgh - Pittsburgh
California
- UCSF Comprehensive Cancer Center - San Francisco
District of Columbia
- Children's National Medical Center - Washington D.C.
Massachusetts
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute - Boston
North Carolina
- Duke Comprehensive Cancer Center - Durham
Tennessee
- St. Jude Children's Research Hospital - Memphis
Texas
- Texas Children's Cancer Center - Houston
Washington
- Children's Hospital and Regional Medical Center - Seattle - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2002-01 |
| Est. Completion | 2007-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00015899
The ClinicalTrials.gov registry entry for NCT00015899 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (71% lower). The listed sponsor is Pediatric Brain Tumor Consortium, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 1 intervention - of which lonafarnib is the first listed.
NCT00015899 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Pennsylvania, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00015899 about?
NCT00015899 is a clinical study titled "SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors". RATIONALE: SCH 66336 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SCH 66336 in treating children with recurrent or progressive brain tumors.
What is the current status of trial NCT00015899?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2002-01. Estimated completion is 2007-03.
What conditions does trial NCT00015899 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00015899?
The interventions under investigation include: lonafarnib (DRUG).
Who is sponsoring clinical trial NCT00015899?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00015899 being conducted?
This trial has 9 study locations across California, District of Columbia, Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunotoxin Therapy in Treating Patients With Malignant Glioma
COMPLETED · Phase 1
-
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
COMPLETED · Phase 1
-
Sirolimus in Treating Patients With Glioblastoma Multiforme
COMPLETED · Phase 1
-
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
COMPLETED · Phase 1
-
Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors
COMPLETED · Phase 1
-
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.